Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer.

about

Emerging technologies in the delivery of erythropoietin for therapeutics.

P2860

Q37646523-D237ECDE-BDAD-4406-A018-72A29CDCD267

P2860

Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer.

Item

http://www.wikidata.org/entity/Q36256405

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Anemia is a common but neglect ...... erapy for early breast cancer.

@ast

Anemia is a common but neglect ...... erapy for early breast cancer.

@en

type

Item

label

Anemia is a common but neglect ...... erapy for early breast cancer.

@ast

Anemia is a common but neglect ...... erapy for early breast cancer.

@en

prefLabel

Anemia is a common but neglect ...... erapy for early breast cancer.

@ast

Anemia is a common but neglect ...... erapy for early breast cancer.

@en

P1476

Anemia is a common but neglect ...... erapy for early breast cancer.

@en

P2093

A Goldrick

http://www.w3.org/2001/XMLSchema#string

C H Speers

http://www.w3.org/2001/XMLSchema#string

C S Alexander

http://www.w3.org/2001/XMLSchema#string

I A Olivotto

http://www.w3.org/2001/XMLSchema#string

J Barnett

http://www.w3.org/2001/XMLSchema#string

P T Truong

http://www.w3.org/2001/XMLSchema#string

S J Allan

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy-induced anemia in adults: incidence and treatment.

Medical paternalism and expensive unsubsidised drugs.

Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes.

The level of haemoglobin in anaemic cancer patients correlates positively with quality of life

Functional significance of erythropoietin receptor expression in breast cancer.

Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy.

Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey.

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.

P304

227-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.2007.156

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5768607

http://www.w3.org/2001/XMLSchema#string

P698

18080014

http://www.w3.org/2001/XMLSchema#string

P932

2133099

http://www.w3.org/2001/XMLSchema#string

Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer.

about

P2860

P2860

Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932